A Comparative, Multicenter, Placebo-Controlled, Double-Blind Phase II Clinical Trial Evaluating the Efficacy, Safety and Tolerability of Inhaled Aviptadil in Patients 18 Years and Older With COVID-19 Pulmonary Involvement - HOPE
Latest Information Update: 07 Jun 2023
Price :
$35 *
At a glance
- Drugs Aviptadil (Primary)
- Indications COVID-19 pneumonia; SARS-CoV-2 acute respiratory disease
- Focus Therapeutic Use
- Acronyms HOPE
- Sponsors Centurion Pharma
- 02 Jun 2023 Status changed from recruiting to completed.
- 16 Apr 2021 New trial record